Figure 1.
Non-volatile compounds of rice bran. Inpari 30 non-fermented (IPRNF); Inpari 30 fermented (IPRF); Cempo Ireng non-fermented (CINF); and Cempo Ireng fermented (CIF).
Researchers have long regarded photovoltaics (PV) as a poor energy return (ER) compared to fossil fuels. Although the latter's energy-return-on-investment (EROI), like oil, coal, and gas, are above 25:1 at the primary, they are about 6:1 at the final stage. Following the technology creation, it is essential to investigate whether the solar module technology innovation affects the ER. Much literature delivers the ERs of fossil fuels and PV. However, it does not address the life cycle analysis or life cycle energy analysis (LCEA) assessments. This paper, employing time-series and LCEA analyses, performs an ER evaluation of the 181-MWp global most extensive offshore floating PV (OFPV) in a 30-year life cycle at Changhua Coastal Industrial Park, Taiwan. The results show that the energy payback time (EPBT) is about one year. The EROI is about 29.8, which is superior or complies with the upper limits of previous studies under the same insolation. The approach proposed in this study should help future PV stations' ER analysis and clarify whether the innovation benefits from improving the system's performance. The results also assist in investors' decision-making regarding deploying PV projects in the future.
Citation: Ching-Feng CHEN. Offshore floating photovoltaic system energy returns assessment—A life cycle energy analysis-based perspective[J]. AIMS Energy, 2023, 11(3): 540-554. doi: 10.3934/energy.2023028
| [1] | Thornthan Sawangwan, Chompoonuth Porncharoennop, Harit Nimraksa . Antioxidant compounds from rice bran fermentation by lactic acid bacteria. AIMS Agriculture and Food, 2021, 6(2): 578-587. doi: 10.3934/agrfood.2021034 |
| [2] | Santi Noviasari, Feri Kusnandar, Agus Setiyono, Slamet Budijanto . Antioxidant activity and inhibition of α-amylase and α-glucosidase in fermented black rice bran-based analog rice. AIMS Agriculture and Food, 2022, 7(1): 61-72. doi: 10.3934/agrfood.2022004 |
| [3] | Budi Suarti, Sukarno, Ardiansyah, Slamet Budijanto . Bio-active compounds, their antioxidant activities, and the physicochemical and pasting properties of both pigmented and non-pigmented fermented de-husked rice flour. AIMS Agriculture and Food, 2021, 6(1): 49-64. doi: 10.3934/agrfood.2021004 |
| [4] | Rita Khathir, Murna Muzaifa, Yunita, Marai Rahmawati . Study on the physicochemical and sensory profile of pliek-u: A traditional dried fermented coconut endosperm from Aceh, Indonesia. AIMS Agriculture and Food, 2023, 8(2): 534-549. doi: 10.3934/agrfood.2023028 |
| [5] | Nur Fajriani Suaib, Didah Nur Faridah, Dede Robiatul Adawiyah, Nuri Andarwulan . Semiquantification of volatile compounds and identification of potential volatile markers and dry aroma from robusta second-crack roasted coffee processed from several post-harvest processing. AIMS Agriculture and Food, 2025, 10(1): 74-96. doi: 10.3934/agrfood.2025005 |
| [6] | Sapta Raharja, Yogi Purna Rahardjo, Samsudin, Khaswar Syamsu . Aroma precursor enhancing in dried cocoa beans fermentation using enzyme and heat addition. AIMS Agriculture and Food, 2023, 8(2): 674-686. doi: 10.3934/agrfood.2023037 |
| [7] | Alexandros Tsoupras, Eirini A. Panagopoulou, George Z. Kyzas . Anti-inflammatory, antithrombotic and anti-oxidant bioactives of beer and brewery by-products, as ingredients of bio-functional foods, nutraceuticals, cosmetics, cosmeceuticals and pharmaceuticals with health promoting properties. AIMS Agriculture and Food, 2024, 9(2): 568-606. doi: 10.3934/agrfood.2024032 |
| [8] | Anderson de Moura Zanine, Breno de Moura Gimenez, Daniele de Jesus Ferreira, Michelle de Oliveira Maia Parente, Henrique Nunes Parente, Edson Mauro Santos, Glayciane Costa Gois, Fleming Sena Campos, Luana Milena Pinheiro Rodrigues, Jessica Maria de Sousa Oliveira, Nelquides Braz Viana, Daimy Salas Aguilar, George de Sousa Lima Paiva, Dilier Olivera Viciedo . Nutritional parameters of sheep fed diets based on grass silage with brewery residue and a concentrate with rice bran. AIMS Agriculture and Food, 2024, 9(4): 1049-1063. doi: 10.3934/agrfood.2024056 |
| [9] | Dody Dwi Handoko, Anisa Maharani Kaseh, Laras Cempaka, Wahyudi David, Bram Kusbiantoro, Afifah Zahra Agista, Yusuke Ohsaki, Hitoshi Shirakawa, Ardiansyah . Effects of household-scale cooking on volatile compounds, sensory profile, and hypotensive effect of Kenikir (Cosmos caudatus). AIMS Agriculture and Food, 2023, 8(1): 198-213. doi: 10.3934/agrfood.2023011 |
| [10] | Orbe Chamorro Mayra, Luis- Armando Manosalvas-Quiroz, Nicolás Pinto Mosquera, Iván Samaniego . Effect of fermentation parameters on the antioxidant activity of Ecuadorian cocoa (Theobroma cacao L.). AIMS Agriculture and Food, 2024, 9(3): 872-886. doi: 10.3934/agrfood.2024047 |
Researchers have long regarded photovoltaics (PV) as a poor energy return (ER) compared to fossil fuels. Although the latter's energy-return-on-investment (EROI), like oil, coal, and gas, are above 25:1 at the primary, they are about 6:1 at the final stage. Following the technology creation, it is essential to investigate whether the solar module technology innovation affects the ER. Much literature delivers the ERs of fossil fuels and PV. However, it does not address the life cycle analysis or life cycle energy analysis (LCEA) assessments. This paper, employing time-series and LCEA analyses, performs an ER evaluation of the 181-MWp global most extensive offshore floating PV (OFPV) in a 30-year life cycle at Changhua Coastal Industrial Park, Taiwan. The results show that the energy payback time (EPBT) is about one year. The EROI is about 29.8, which is superior or complies with the upper limits of previous studies under the same insolation. The approach proposed in this study should help future PV stations' ER analysis and clarify whether the innovation benefits from improving the system's performance. The results also assist in investors' decision-making regarding deploying PV projects in the future.
Rice is a staple food in Indonesia, which is one of the largest rice producers in the world. According to BPS-Statistics Indonesia, rice production touched 54.60 million tons in 2019 [1]. Polished rice is the primary product of rice, of which rice bran is the main by-product, followed by rice husk and germ. Rice bran consists of 8-12 percent of the by-product from the rice milling process [2].
Rice bran is used mainly as animal feed in Indonesia. There are not many studies on bioactivity, especially using animal model of diseases. Several studies show the potency of rice bran as food, especially as a functional ingredient, due to its beneficial bioactive compound content. The active bioactive compounds of rice bran are γ-oryzanol, polyphenols, phytosterols, tocopherols, tocotrienols, adenosine, ferulic acid, and adenosine, which can function as antioxidants and chemopreventive agents, with properties of lowering blood pressure and regulating cholesterol synthesis [3,4,5,6] Further, in some pigmented rice cultivars, rice bran is the part where the pigment is concentrated. The well-known pigmented rice in Indonesia is black rice. Black rice bran has a higher total phenolic content (TPC), anthocyanins, flavonoids, and antioxidant activity than polished red and white rice bran [7].
Solid-state fermentation (SSF) is known to enhance the bioactive compounds of rice bran [8]. This method uses solid media for microbial growth. The advantages of SSF are avoidance of lipid hydrolysis, minimum water requirements, low risk of contamination, and high yield of fermentation product [9]. Earlier studies and our own showed that SSF, by using Rhizopus oligosporus, can increase TPC and antioxidant activity [10,11]. Further, our results showed that SSF with R. oligosporus offers the optimum fermentation conditions for rice bran in Inpari 30 and Cempo Ireng for 72 hours at 30 ℃ [11].
The non-volatile compounds in rice bran have been studied in varieties of Calrose, Dixiebelle, and Neptune [12,13]. 453 compounds were found, consisting of amino acids, carbohydrates, vitamins and cofactors, lipids, nucleotides, peptides, secondary metabolites, and xenobiotics. Other studies have shown that fermentation treatment affects the number and diversity of bioactive compounds of rice bran [14]. Based on these findings, the non-volatile compounds of fermented and non-fermented rice bran may differ between rice varieties. Research has not been carried out on the non-volatile compounds in fermented and non-fermented bran, especially for rice bran varieties in Indonesia. Therefore, the purpose of this study was to analyze and compare non-volatile compounds of fermented and non-fermented rice bran of two varieties -i.e., Inpari 30 (IPR30) and Cempo Ireng (CI)- and their blood pressure lowering activity, by using a spontaneously hypertensive animal model. The IPR30 cultivar, another Ciherang cultivar (white rice) widely consumed in Indonesia and CI black rice cultivar, a variety of local pigmented rice planted in Bogor-West Java, Indonesia, were studied in this regard.
The sample used in this study was brown rice IPR30 obtained from Indonesian Center for Rice Research, Indonesian Agency for Agricultural Research and Development, Ministry of Agriculture, Subang, West Java, Indonesia and paddy CI from the local farmer in Bogor, West Java, Indonesia. Paddy of CI was de-hulled by a Rice Machine-THU (Satake, Japan) to obtain brown rice. Two types of brown rice were polished by mini rice mill processing (Satake Grain Testing Mill, Hiroshima, Japan) as described previously [11]. The samples were divided into non-fermented IPR30 rice bran (IPRNF), fermented IPR30 rice bran (IPRF), non-fermented CI rice bran (CINF), and fermented CI rice bran (CIF).
R. oligosporus were obtained from the Indonesian Culture Collection, Research Center for Biology, the Indonesian Institute of Science, Cibinong, Indonesia. The R. oligosporus were asseverated on potato dextrose agar media. The preparation of the culture and fermentation process followed the method used in a previous study [11]. The fermented and non-fermented samples were freeze-dried using a freeze-dryer (Labconco, USA) before further analysis.
Sample extraction was done as described by [15,16], with modifications. Samples were dissolved in distilled water with 20% (w/v). The solutions were centrifuged (5223 x g, 10 minutes, 4 ℃) and then extracted by the solid phase extraction method. For every five mL of supernatant, one ml of lidocaine (internal standard) was added, resulting in 2.0083 µM of lidocaine in the supernatant. Thereafter, six ml of solution two was inserted into the cartridge (Oasis HLB 12 mL). Samples were vacuumed to remove their water and salt content. Samples were then eluted with methanol 5% and 1.5 mL were collected for analysis. For the animal study, the water extract of fermented RB was used by an oral single dose experiment.
Non-volatile compounds were analyzed using Ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), as described in [12] with modifications. The liquid chromatography instrument used in this study was Waters ACQUITY UPLC H-Class System with C18 column (1.8 µm, 2.1 × 100 mm) at 50 ℃, while the mass spectrometry was Xevo G2-S quadrupole time-of-flight mass spectrometry (QToF-MS/MS) with electrospray ionization spray (ESI) system. For MS, the ion positive mode was used between 70-1000 m/z. Before injection, samples were filtered with a 0.2 µm syringe filter. Five µL of the sample was injected with mobile phase (A), 0.1% formic acid in water and (B), 0.1% formic acid in methanol (0% B to 70% B for 4 minutes, 70-98% B for 0.5 minutes, 98% B for 0.9 minutes). The observed injection flow rate was 0.2 mL per minute for 23 minutes. Masslynx v4.1 was used to identify the non-volatile compounds in the sample. The non-volatile compound data were then cross-checked with MassBank, Human Metabolome Database (HMDB) and Kyoto Encyclopedia of Genes and Genomes (KEGG) data [13]. The relative concentration of non-volatile compounds in the sample were determined by comparing the percentage area between sample and internal standard (lidocaine), based on the concentration of internal standard. The relative concentration was then converted into ppm units.
The male SHRSP/Izumo strain (Japan SLC, Shizuoka, Japan) was used in these studies. The rats were housed in individual stainless-steel cages in a controlled atmosphere (temperature, 23 ± 2 ℃; humidity, 50 ± 10%; 12 h light-dark cycle) as per a previous study [4]. The Animal Research-Animal Care Committee approved the experimental plan for the present study of Tohoku University (2016AgA-024). The entire experiment was conducted following the guidelines issued by this committee and Japanese governmental legislation (2005). The water extract of fermented RB (CI and IPR30, 72 h fermentation) was used to determine the BP-lowering effect in SHRSP. The number of animals used in this study, concentration of the sample in the treated group, and control were similar to our previous study [11]. The blood pressure measurement was by the tail-cuff method with a BP meter as described in the previous study [4].
The data are described as the mean ± SD. One way analysis of variance using SPSS version 22.0 was performed by two-way analysis (SPSS, Inc., Chicago, IL, USA) followed by Duncan's multiple range test for blood pressure study. The categorization of non-volatile compounds based on their relative concentration was analyzed by principal component analysis (PCA) with XLSTAT 2019.
The non-volatile compounds of fermented and non-fermented rice bran of Inpari 30 and Cempo Ireng are presented in Supplementary Table 1. These were classified into 36 secondary metabolites, 16 lipids, 8 amino acids, 7 vitamins and cofactors, 3 peptides, one carbohydrate, and one nucleotide (Figure 1). Fermentation of Inpari 30 and Cempo Ireng rice bran produced new compounds that were not found in the non-fermented samples.
The highest concentration of secondary metabolites found in IPRNF consisted of n, n-diethyl phenylacetamide (MS25), while in IPRF rice bran, the contents were dominated by 2-acetylpyrrole (MS29) and momilactone B (MS7). A study on n, n-diethyl phenylacetamide has shown that it can be used as an insect repellent [17] and 2-acetylpyrrole has hepatoprotective properties [18]. Several studies have shown momilactone B exhibiting inhibitory activities on α-amylase and α-glucosidase, as well as anti-cancer activities by increasing apoptosis in cancer cells [19,20]. In CINF rice bran, the dominant secondary metabolites were myrigalone A (MS36), kojic acid (MS9) and 4-methylbenzoic acid (MS11). Myrigalone A has been known to show antibacterial properties and kojic acid is a chelating agent produced during aerobic fungal fermentation [21].
The most abundant compounds from the lipid in IPRNF and IPRF were leukotriene A4 (LD8) and aminocaproic acid (LD6). The dominant lipid compounds in CINF and CIF were lacinilene C 7-methyl ether (LD2) and phytosphingosine (LD9) respectively. Lacinilene C 7-methyl ether is known to have antibacterial properties [22]. Phytosphingosine has shown anti-inflammatory and antibacterial properties in skin disorders, besides playing a role in transcription activation in peroxisome proliferator-activated receptor [23,24].
Amino acids with the highest concentration found in IPRNF and IPRF were norvaline (AA2) and l-phenylalanine (AA7) respectively. Norvaline is a byproduct of branched-chain amino acid synthesis, which can also act as arginase inhibitor [25]. L-phenylalanine is involved in neurotransmitters, hormones, and skin pigment synthesis in humans [26]. The highest concentration of amino acids in CINF and CIF were 3-methyldioxyindole (AA6) and indoleacrylic acid (AA8) respectively. Indoleacrylic acid has been known to be produced during tryptophan degradation.
The dominant compounds found in the vitamins and cofactors group in IPRNF and IPRF were trigonelline (VK5) and pantothenic acid (VK2) respectively. Trigonelline is found only in IPRNF rice bran and is involved in treating diabetes by lowering the blood glucose level, increasing insulin sensitivity, and decreasing lipid peroxidation [27]. Pantothenic acid is synthesized by R. oligosporus from β-alanine and pantoic acid [28]. The dominant compound in the vitamins and cofactors in CINF and CIF were nicotinic acid (VK1) and 7-aminomethyl-7-carbaguanine (VK6), respectively. Nicotinic acid prevents atherosclerosis by increasing high-density lipoprotein, and decreasing triglyceride level and oxidative stress [29].
Non-volatile compounds from the peptide group were detected only in the fermented samples. The most abundant peptide found in IPRF and CIF were phenylalanyl-isoleucine (PD3) and leucyl-isoleucine (PD2), respectively. According to an earlier study, Leucyl-isoleucine increases monocytes and platelet level in rats and stimulates AMPK phosphorylation [30,31].
Principal component analysis (PCA) was applied to compare the differences of quantum in non-volatile compounds among the samples. The PCA of non-volatile compounds is shown in Figure 2. Non-fermented rice bran samples (IPRNF and CINF) were located in a quadrant different from fermented rice bran (IPRF and CIF), indicating that fermentation influenced non-volatile compound production. Adenosine (NA) generally was found the most in non-volatile compounds across all the samples. In the fermented sample of Inpari 30, the level of n, n-diethyl phenylacetamide (MS25), indoleacrylic acid (AA8), and l-phenylalanine (AA7) were higher, compared to non-fermented rice bran. Other major non-volatile compounds found in IPRNF samples were leukotriene A4 (LD8) and trigonelline (VK5).
On the other hand, fermentation of the Cempo Ireng variety showed an increase in quercetin (MS15), isorhamnetin 7-glucoside (MS16), isorhamnetin (MS17), and nicotinic acid (VK1) levels. In Cempo Ireng samples, the non-volatile compounds with the highest concentration after adenosine were different. In CINF, it was myrigalone A (MS36), while CIF leucyl-isoleucine (PD2) and phenylalanyl-isoleucine (PD3) showed similar concentrations. These compounds are likely to have originated from arachidonic acid, nicotinic acid and nicotinamide, phenylalanine, tryptophan, and dipeptide metabolism. The major non-volatile compounds from each classification from PCA analysis are summarized in Figure 3. The list of non-volatile compounds and its statistical analyses shown in Supplementary Table 1 (Supplementary data).
Adenosine is a compound necessary for production of energy within the body, and is created from purine metabolism. As a phytochemical found in rice bran, adenosine has the effect of lowering blood pressure, helps to treat hyperlipidemia, increases insulin activity, and preventing hypertension in the stroke-prone spontaneously hypertensive rat (SHRSP) [5]. In humans, adenosine has neuromodulator and neuroprotective functions, reduces epilepsy, and regulates the sleep cycle [32,33,34].
Several studies of these compounds have shown them to have beneficial effects for the body, which includes lowering blood pressure, improving the immune and digestive systems, as well as having neuromodulator, neuroprotective, chemo preventive and antidiabetic properties. Further, other studies have also found that these bioactive compounds play a part in preventing gastric ulcer and improving hormone and melanin synthesis [26,27,30,32].
The proposed metabolic pathways found in rice bran are shown in Figure 4. Previous studies shown that rice bran has contained non-volatile compounds (12-14). Our study carried out non-volatile compound of fermented and non-fermented rice bran varieties in Indonesia. Pathways related to the compounds in the fermented and non-fermented Inpari 30 rice bran were the metabolism of valine and the citric acid cycle, respectively. Folate metabolism was found in fermented Cempo Ireng rice bran, while pentatonic acid, vitamin B6, and benzoxazinoid metabolism were found in non-fermented Cempo Ireng rice bran. Fermented versions of both fermented Inpari 30 and Cempo Ireng rice bran produced compounds from the metabolism of tyrosine, phenylalanine, pantothenic acid and dipeptide that was not detected in the non-fermented samples.
Non-volatile compounds in fermented Inpari 30 and Cempo Ireng rice brans were identified as metabolic pathways from tyrosine, phenylalanine, pantothenic acid, folic acid, dipeptide, terpenoid, and sphingolipid. The presence of dipeptide and amino acid compounds indicated that the samples were attributed to rice bran protein degradation by R. oligosporus-synthesized protease [35]. Similarly, metabolites of pantothenic and folic acid were also utilized by fungi, as they are components necessary for fungal metabolic activities [36]. Comparatively, compounds from sphingolipid metabolism are commonly found in fungal plasma membrane [37]. Fungi sphingolipids known to be involved in hyphal morphogenesis are produced during sphingolipid metabolism with serine and palmitoyl-CoA as its precursor [38,39], similar to the terpenoid found in fermented rice bran produced by the fungal mevalonate pathway [40].
This study also investigated whether fermented RB showed any blood pressure-lowering effects after administration of a single oral dose (40 mg/kg body weight) (Table 1). Twelve-week-old male SHRSP with a systolic blood pressure (sBP) of approximately 170 mmHg, were used in this study. The result showed that there was similar sBP of the control group before and after administration. The sBP showed a significant decrease after 6h administration of IPRF (p < 0.05), compared to the control group. A blood pressure lowering activity was also found as sBP was decreasing from 2 h after administration until the end of the study. This study was consistent with the previous study by using Inpari 30 fermented RB [11]. Further, this study also showed evidence of adenosine as one of the identified bioactive compounds in rice bran [5].
| Group | 0 h | 2 h | 4 h | 6 h |
| Control | 172.3 ± 13.1 | 172.0 ± 8.1 | 161.3 ± 6.5 | 168.0 ± 3.0 |
| CIF | 176.8 ± 9.1 | 175.3 ± 2.9 | 165.3 ± 13.3 | 166.8 ± 8.5 |
| Change b (%) | - | +1.9 | +2.4 | −0.7 |
| IPRF | 171.3 ± 5.0 | 152.3 ± 14.3 | 142.0 ± 12.4 | 141.5 ± 12.2* |
| Change b (%) | - | −12.9 | −13.6 | −18.7 |
| Note: a Values are given as means ± SD, n = 4. *A significantly different (p < 0.05) versus Control after statistical analysis by one-way analysis of variance using SPSS version 22 software (SPSS, Inc., Chicago, IL, USA) followed by Duncan's multiple range test. | ||||
DownLoad:
CSV
This study strengthened the proposition that IPRF is a good source of functional ingredient that can be effective in decreasing hypertension in an animal model of metabolic syndrome-related diseases. Future studies are required to specify the IPRF mechanism of blood pressure-lowering activity and other functionalities in relation to metabolic diseases.
Different rice varieties and fermentation processes influence the concentration and types of non-volatile compounds in rice bran. Adenosine was found to have the greatest concentration of non-volatile compound in rice bran. Fermentation of rice bran samples from IPR30 and CI varieties generated compounds from tyrosine, phenylalanine, pentatonic acid, dipeptide, sphingolipid and terpenoid metabolism, which were not found in the non-fermented rice bran. Fermentation of rice bran can produce and enhance non-volatile compounds as anti-hypertensive effect in an animal model of hypertension. Further, this study found adenosine to be a useful marker for non-volatile compounds in rice bran.
We would like to thank to the Ministry Research and Technology/BRIN RI for research funding. The partial of the research was supported by a grant from the collaboration research of JSPS and DIKTI RI.
All authors declare no conflict of interest.
| Compounds | Codes | HMDB ID | Relative Concentrations (ppm) | Effects | References | |||
| Inpari 30 | Cempo Ireng | |||||||
| Non-fermented | Fermented | Non-fermented | Fermented | |||||
| (Amino acids) | ||||||||
| Meta-tyrosine | AA1 | 0059720 | ND | 0.0266* | ND | ND | Immunoprotective | [41] |
| Reduces metastasis | [42] | |||||||
| Norvaline | AA2 | 0013716 | 0.0253* | 0.0008* | ND | ND | Arginase inhibitor | [31] |
| N-Acetyltryptophan | AA3 | 0013713 | ND | 0.0039* | ND | ND | Antioxidant | [43] |
| 1H-Imidazole-1-acetic acid | AA4 | 0029736 | ND | ND | ND | 0.0033* | - | - |
| L-DOPA | AA5 | 0000181 | ND | ND | ND | 0.0050* | Treatment of Parkinson Dissease (by increasing dopamine levels in brain) | [44] |
| 3-Methyldioxyindole | AA6 | 0004186 | ND | ND | 0.0011 ± 0.0003 | ND | - | - |
| L-Phenylalanine | AA7 | 0000159 | ND | 0.2413 ± 0.2051a | ND | 0.0360 ± 0.0080b | Neurotransmitter synthesis, hormones and pigments synthesis | [26] |
| Indoleacrylic acid | AA8 | 0000734 | 0.0115*a | 0.1806 ± 0.1412b | ND | 0.0395 ± 0.0011a | Improves the instentines functions | [45] |
| (Carbohydrates) | ||||||||
| Succinic acid | KH | 0000254 | 0.0002* | ND | ND | ND | Antioxidant, Imrpove the immune and nervous functions | [46] |
| (Lipids) | ||||||||
| Cincassiol B | LD1 | 0036855 | ND | 0, 0208* | ND | ND | - | - |
| Lacinilene C 7-methyl ether | LD2 | 0036456 | 0.0129 ± 0.0015 | 0.0058* | 0.0134* | 0.0023* | Antimicrobial | [22] |
| Valdiic acid | LD3 | 0040980 | ND | 0.0088 ± 0.0108 | ND | ND | - | - |
| Prostaglandin C1(1-) | LD4 | 0062756 | 0.0102 ± 0.0029 | ND | 0.0090 ± 0.0017 | ND | - | - |
| 10-Oxo-11-octadecen-13-olide | LD5 | 0029786 | 0.0041* | ND | 0.0109* | ND | - | - |
| Aminocaproic acid | LD6 | 0001901 | ND | 0.0390* | ND | 0.0037* | Antifibrinolytic | [47] |
| L-Octanoylcarnitine | LD7 | 0000791 | ND | 0.0180* | 0.0091 ± 0.0052 | ND | - | - |
| Leukotriene A4 | LD8 | 0029016 | 0.0352 ± 0.0288 | 0.0131 ± 0.0063 | 0.0110* | ND | The parent molecule for the biosynthesis of all leukotrienes | [48] |
| Phytosphingosine | LD9 | 0004610 | ND | 0.0126*b | 0.0114 ± 0.0031a | 0.0049 ± 0.0042b | ● Anti-inlammatory and antibacterial in skin disorders | [31] |
| ● Activates the transcription activity on PPAR | [23] | |||||||
| (Ent-2alpha, 3beta, 15beta, 16beta)-15, 16-Epoxy-2, 3-kauranediol | LD10 | 0038688 | 0.0201 ± 0.0099b | ND | 0.0019*a | ND | - | - |
| Dehydroabietic acid | LD11 | 0031127 | 0.0263* | ND | ND | ND | ● Anti-inflammatory in obese people | [49] |
| ● Activates the SIRT1 enzymes | [50] | |||||||
| 13, 14-Dihydro-15-keto-PGE2 | LD12 | 0002776 | ND | ND | 0.0010* | ND | Increases the growth of pancreatic celss | [51] |
| 3-hydroxyundecanoyl carnitine | LD13 | 0061637 | ND | ND | 0.0102 ± 0.0031 | ND | - | - |
| Leukotriene C4 | LD14 | 0001198 | 0.0095* | ND | ND | ND | Lipid mediator for inflammation | [52] |
| 5-Hexyltetrahydro-2-furanoctanoic acid | LD15 | 0029018 | 0.0105* | ND | 0.0021* | ND | - | - |
| (Z)-13-Oxo-9-octadecenoic acid | LD16 | 0029796 | 0.0094* | 0.0072* | ND | ND | - | - |
| (Nucleotides) | ||||||||
| Adenosine | NA | 0000050 | 0.0838 ± 0.1053 | 0.4323 ± 0.1236 | 0.2119 ± 0.0142 | 0.3007 ± 0.1602 | ● Neuromodulator | [34] |
| ● Neuroprotective | [33] | |||||||
| ● Reduces epilepsy | [32] | |||||||
| ● Regulates the sleep cycle | [53] | |||||||
| ● Lowering blood pressure | [5] | |||||||
| (Secondary Metabolites) | ||||||||
| Cohumulone | MS1 | 0033981 | ND | 0.0052* | ND | ND | Aldo keto reductase inhibitors | [54] |
| 3-O-Methylmethyldopa | MS2 | 0142154 | ND | 0.0022 ± 0.0005 | ND | ND | - | - |
| 2, 6-Dimethoxy-4-propylphenol | MS3 | 0036226 | ND | 0.0007 ± 0.0001 | ND | ND | - | - |
| Alpha-curcumene | MS4 | 0059878 | ND | 0.0017±0.0004 | ND | ND | ● Antimicrobial | [55] |
| ● Induced apoptosis | [56] | |||||||
| Cuscohygrine | MS5 | 0030290 | ND | 0.0033* | 0.0051* | 0.0028* | - | - |
| 3-Tert-butyl-4-hydroxyanisole | MS6 | 0059925 | ND | 0.0015* | 0.0184* | ND | The building blocks of butylated hydroxyanisole (BHA) | [57] |
| Momilactone B | MS7 | 0036749 | ND | 0.0153* | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| ● Cancer chemopreventive | [19] | |||||||
| 2-Indolecarboxylic acid | MS8 | 0002285 | 0.0024* | ND | 0.0023* | ND | Antioxidant | [58] |
| Kojic acid | MS9 | 0032923 | 0.0061 ± 0.0016 | ND | 0.0103 ± 0.0010 | ND | ● Tyrosinase inhibitors | [59] |
| ● Immunomodulator | [9] | |||||||
| L-1, 2, 3, 4-Tetrahydro-beta-carboline-3-carboxylic acid | MS10 | 0035665 | 0.0008* | ND | ND | ND | - | - |
| 4-Methylbenzoic acid | MS11 | 0029635 | 0.0010*a | ND | ND | 0.0385 ± 0.0103b | - | - |
| 2-Methylhippuric acid | MS12 | 0011723 | 0.0006* | ND | ND | ND | - | - |
| Momilactone A | MS13 | 0036748 | 0.0020* | ND | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| Coumarin | MS14 | 0001218 | 0.0009* | ND | ND | ND | ● Antimicrobial | [60) |
| ● Acetylcholinesterase (AChE) inhibitor | [61] | |||||||
| Quercetin | MS15 | 0005794 | ND | ND | 0.0050 ± 0.0031 | 0.0057 ± 0.0028 | ● Antioxidant | [62] |
| ● Decreases activation of dendytic celss for the treatment of inflammation, autoimmunity and transplantation | [61] | |||||||
| ● Antiviral activity against dengue fever | [63] | |||||||
| ● Lowering blood pressure in people with hypertension | [64] | |||||||
| ● Reduces symptoms of non-alcoholic fatty liver dissease | [65] | |||||||
| Isorhamnetin 7-glucoside | MS16 | 0029479 | ND | ND | 0.0089 ± 0.0050 | 0.0165 ± 0.0009 | Antioxidant | [66] |
| Isorhamnetin | MS17 | 0002655 | ND | ND | 0.0048* | 0.0121* | Treats cerebral vascular complications associated with diabetes | [67] |
| 2-Hydroxy-2-phenylpropanoic acid | MS18 | 0142137 | ND | ND | 0.0045 ± 0.0007a | 0.0029 ± 0.0013b | - | - |
| 2-Phenylpropionaldehyde dimethyl acetal | MS19 | 0032468 | ND | ND | ND | 0.0055 ± 0.0022 | - | - |
| Naringenin | MS20 | 0002670 | ND | ND | ND | 0.0037* | ● Hepatoprotector | [68] |
| ● Reduces TNF- α production | [69] | |||||||
| ● Anti-hyperglycemia | [70] | |||||||
| ● Cardioprotective | [71] | |||||||
| ● Antiviral activity against dengue fever | [72] | |||||||
| ● Inhibits the proliferation and migration of prostate cancer cells | [73] | |||||||
| Phenprocoumon | MS21 | 0015081 | ND | ND | ND | 0.0058* | ● Anticoagulant | [74] |
| Isovanillic acid | MS22 | 0060003 | ND | ND | 0.0042 ± 0.0011 | ND | ● Antibacterial | [75] |
| ● Antioxidant | [76] | |||||||
| Antimicrobial | [60] | |||||||
| 2, 6-Dimethoxybenzoic acid | MS23 | 0029273 | ND | ND | 0.0106* | ND | - | - |
| Benzoic acid | MS24 | 0001870 | ND | ND | 0.0009 ± 0.0003 | ND | Inhibits the growth of resistant bacteria | [77] |
| N, N-diethyl phenylacetamide | MS25 | 0032635 | 0.0090* | 0.0096* | 0.0066* | 0.0263* | Mosquitos repellent | [17] |
| Oryzalide B | MS27 | 0037592 | ND | ND | ND | 0.0053 ± 0.0032 | Antibacterial | [78] |
| Acetylvalerenolic acid | MS28 | 0035687 | ND | ND | ND | 0.0045* | - | - |
| MS29 | 0035882 | ND | 0.0309 | ND | ND | Hepatoprotector | [18] | |
| Dimboa-glc | MS30 | 0029710 | ND | ND | 0.0089 ± 0.0056 | ND | - | - |
| 2-Decylfuran | MS31 | 0032215 | ND | ND | ND | 0.0015 | - | - |
| Piperenol A triacetate | MS32 | 0041535 | ND | 0.0129* | ND | ND | - | - |
| Ginsenoyne G | MS33 | 0039589 | ND | ND | 0.0025 | ND | - | - |
| Acetylpterosin C | MS34 | 0030764 | 0.0053* | ND | ND | ND | - | - |
| 1, 3, 11-Tridecatriene-5, 7, 9-triyne | MS35 | 0034294 | ND | ND | 0.0160 | ND | - | - |
| Myrigalone A | MS36 | 0037245 | ND | ND | 0.0278* | 0.0256* | Antibacterial | [79] |
| (Vitamins dan cofactors) | ||||||||
| Nicotinic acid | VK1 | 0001488 | 0.0114 ± 0.0007 | ND | 0.0060 ± 0.0025 | 0.0076 ± 0.0009 | Increases HDL cholesterol and lowers triglycerides for the treatment of atherosclerosis | [29] |
| Pantothenic acid | VK2 | 0000210 | ND | ND | ND | 0.0028 ± 0.0010 | Substrates for the synthesis of coenzyme A and ACP (acyl carrier protein) | [80] |
| 2-Hydroxypyridine | VK3 | 0013751 | 0.0008* | ND | ND | ND | - | - |
| 4-Methyl-5-thiazoleethanol | VK4 | - | 0.0175 ± 0.0014 | ND | 0.0066 ± 0.0021 | ND | - | - |
| Trigonelline | VK5 | 0000875 | 0.0344 ± 0.0247 | ND | ND | ND | ● Increases cell sensitivity to anticancer and apoptotic drugs | [81] |
| ● Prevents gastric ulcer induced by indomethacin | [82] | |||||||
| ● Lowering blood sugar and lipid as well as increasing insulin sensitivity for diabetes | ||||||||
| ● Inhibits neurons loss in hypocampus | [83] | |||||||
| 7-Aminomethyl-7-carbaguanine | VK6 | 0011690 | ND | ND | ND | 0.0132* | - | - |
| Pyridoxal | VK7 | 0001545 | ND | ND | 0.0066 ± 0.0021 | ND | ● Cofactors in various amino acids metabolism | [84] |
| ● Maintains the nervous systems in infants | [85] | |||||||
| (Peptides) | ||||||||
| Leucyl-valine | PD1 | 0028942 | ND | 0.0222 ± 0.0162 | ND | ND | Increases the expression of glutathione peroxidase, antioxidants and cell protection agents | [86] |
| Leucyl-isoleucine | PD2 | 0028932 | ND | 0.0653 ± 0.0436 | ND | 0.0596 ± 0.0263 | Increases the stimulation of AMPK phosphorylation (5'-AMP protein kinase), monocytes, and platelets | [30] |
| Note: The presentation of the relative value data for the compounds comes from the calculation of the average relative area of the compound from 3 replications ± deviation standard; ND = Not Detected; * = compound obtained only in 1 replication; Numbers on the same line with different letters indicate significant differences (p < 0.05). | ||||||||
DownLoad:
CSV
| [1] |
Brockway PE, Owen A, Brand-Correa LI, et al. (2019) Estimation of global final-stage energy-return-on-investment for fossil fuels with comparison to renewable energy sources. Nature Energy 4: 612–621. https://doi.org/10.1038/s41560-019-0425-z doi: 10.1038/s41560-019-0425-z
|
| [2] |
Bhandari KP, Collier JM, Ellingson RJ, et al. (2015) Energy payback time (EPBT) and energy return on energy invested (EROI) of solar photovoltaic systems: A systematic review and meta-analysis. Renewable Sustainable Energy Rev 47: 133–141. https://doi.org/10.1016/j.rser.2015.02.057 doi: 10.1016/j.rser.2015.02.057
|
| [3] |
Gessert TA (2012) Cadmium telluride photovoltaic thin film: CdTe. Compr Renewable Energy 1: 423–438. https://doi.org/10.1016/B978-0-08-087872-0.00122-0 doi: 10.1016/B978-0-08-087872-0.00122-0
|
| [4] |
Murphy DJ, Hall CAS (2010) Year in review EROI or energy return on (Energy) invested. Ann N Y Acad Sci 1185:102–118. https://doi.org/10.1111/j.1749-6632.2009.05282.x doi: 10.1111/j.1749-6632.2009.05282.x
|
| [5] |
Atlason R, Unnthorsson R (2014) Ideal EROI (energy return on investment) deepens the understanding of energy systems. Energy 67: 301–45. https://doi.org/10.1016/j.energy.2014.01.096 doi: 10.1016/j.energy.2014.01.096
|
| [6] |
Weißbach D, Ruprecht G, Huke A, et al. (2013) Energy intensity, EROIs (energy returned on invested), and energy payback times of electricity-generating power plants. Energy 43: 53–58. https://doi.org/10.1016/j.energy.2013.01.029 doi: 10.1016/j.energy.2013.01.029
|
| [7] | Fukurozaki SH, Zilles R, Luís I, et al. (2013) Energy payback time and CO2 emissions of 1.2 kWp photovoltaic roof-top system in Brazil. Smart Grid Clean Energy 2: 1–6. https://doi.org/10.12720/sgce.2.2.164-169 |
| [8] | Alsema EA, Frankl P, Kato K (1998) Energy payback time of photovoltaic energy systems: Present status and prospects. |
| [9] |
Louwen A, Sark VAN WGJHM, Schropp REI, et al. (2015) Lifecycle greenhouse gas emissions and energy payback time of current and prospective silicon heterojunction solar cell designs. Prog Photovoltaics Res Appl 23: 1406–1428. https://doi.org/10.1002/pip.2540 doi: 10.1002/pip.2540
|
| [10] | Kamal M, Rabaia H, Semeraro C, et al. (2022) Recent progress towards photovoltaics' circular economy. J Cleaner Prod, 373. https://doi.org/10.1016/j.jclepro.2022.133864 |
| [11] |
Jackson A, Jackson T (2021) Modelling energy transition risk: The impact of declining energy return on investment (EROI). Ecol Econ 185: 107023. https://doi.org/10.1016/j.ecolecon.2021.107023 doi: 10.1016/j.ecolecon.2021.107023
|
| [12] | Grant C, Garcia J, Hicks A (2020) Environmental payback periods of multi-crystalline silicon photovoltaics in the United States—How prioritizing based on environmental impact compares to solar intensity. Sustainable Energy Technol Assess, 39. https://doi.org/10.1016/j.seta.2020.100723 |
| [13] | Daniela-Abigail HL, Tariq R, Mekaoui Amina ElA, et al. (2022) Does recycling solar panels make this renewable resource sustainable? Evidence supported by environmental, economic, and social dimensions. Sustainable Cities Soc, 77. https://doi.org/10.1016/j.scs.2021.103539 |
| [14] | Liu C, Zhang Q, Lei MZ, et al. (2022) Employing benefit-sharing to motivate stakeholders' efficient investment in waste photovoltaic module recycling. Sustainable Energy Technol Assess, 51. https://doi.org/10.1016/j.seta.2021.101877 |
| [15] |
Wang C, Zhang L, Chang Y, et al. (2021) Energy return on investment (EROI) of biomass conversion systems in China: Meta-analysis focused on system boundary unification. Renewable Sustainable Energy Rev 137: 110652. https://doi.org/10.1016/j.rser.2020.110652 doi: 10.1016/j.rser.2020.110652
|
| [16] |
Zhou Z, Carbajales-Dale M (2018) Assessing the photovoltaic technology landscape: efficiency and energy return on investment (EROI). Energy Environ Sci 11: 603–608. https://doi.org/10.1039/C7EE01806A doi: 10.1039/C7EE01806A
|
| [17] |
Gagnon N, Hall CAS, Brinker LA (2009) Preliminary investigation of energy return on energy 487 investment for global oil and gas production. Energies 2: 490–503. https://doi.org/10.3390/en20300490 doi: 10.3390/en20300490
|
| [18] |
Hall CAS, Lambert JG, Balogh SB (2014) EROI of different fuels and the implications for society. Energy Policy 64: 141–152. https://doi.org/10.1016/j.enpol.2013.05.049 doi: 10.1016/j.enpol.2013.05.049
|
| [19] |
Wynes S, Nicholas KA (2017) The climate mitigation gap: Education and government recommendations miss the most effective individual actions. Environ Res Lett 12: 074030. https://doi.org/10.1088/1748-9326/aa7541 doi: 10.1088/1748-9326/aa7541
|
| [20] |
Choi Y (2014) A study on power generation analysis of floating PV system considering environmental impact. Int J Software Eng Appl 8: 75–84. https://doi.org/10.14257/ijseia.2014.8.1.07 doi: 10.14257/ijseia.2014.8.1.07
|
| [21] |
Trapani K, Santafé M (2014) A review of floating photovoltaic installations: 2007–2013. Prog Photovoltaics: Res Appl 23: 530–532. https://doi.org/10.1002/pip.2466 doi: 10.1002/pip.2466
|
| [22] |
Singh C, Kim Y (1988) An efficient technique for reliability analysis of power systems including time-dependent sources. IEEE Trans Power Syst 3: 1090–1096. https://doi.org/10.1109/59.14567 doi: 10.1109/59.14567
|
| [23] | Bureau of Energy, Ministry of Economic Affairs. Energy Technology Research and Development White Paper 2007. Available from (In Chinese): https://www.moeaboe.gov.tw (retrieved on September 30, 2022). |
| [24] |
Sahu A, Yadav N, Sudhakar K (2016) Floating photovoltaic power plant: a review. Renewable Sustainable Energy Rev 66: 815–30. https://doi.org/10.1016/j.rser.2016.08.051 doi: 10.1016/j.rser.2016.08.051
|
| [25] | Gurfude SS, Kulkarni PS (2019) Energy yield of tracking type floating solar PV plant. In 2019 National Power Electronics Conference (NPEC) (pp. 1–6). IEEE.ISO 14040: 2006 Environmental management—Life cycle assessment—Principles and framework. https://doi.org/10.1109/npec47332.2019.9034846 |
| [26] |
Ali M, Gupta SM (2010) Environmentally conscious manufacturing and product recovery (ECMPRO): A review of the state of the art. J Environ Manage 91: 563–591. https://doi.org/10.1016/j.jenvman.2009.09.037 doi: 10.1016/j.jenvman.2009.09.037
|
| [27] | Klöpffer W, Grahl B (2014) Life Cycle Assessment (LCA): A guide to best practice. Wiley-VCH Verlag GmbH & Co. KGaA, 1–2. https://doi.org/10.1002/9783527655625 |
| [28] | Klöpffer W (2014) Introducing life cycle assessment and its presentation in LCA compendium. In: Klöpffer W (Ed.) Background and Future Prospects in Life Cycle Assessment, Springer, 1–37. https://doi.org/10.1007/978-94-017-8697-3_1 |
| [29] |
Cromratie Clemons SK, Salloum CR, Herdegen KG, et al. (2021) Life cycle assessment of a floating photovoltaic system and feasibility for application in Thailand. Renewable Energy 168: 448–462. https://doi.org/10.1016/j.renene.2020.12.082 doi: 10.1016/j.renene.2020.12.082
|
| [30] |
Huberman N, Pearlmutter D (2008) A lifecycle energy analysis of building materials in the Negev desert. Energy Build 40: 837–848. https://doi.org/10.1016/j.enbuild.2007.06.002 doi: 10.1016/j.enbuild.2007.06.002
|
| [31] |
Fay R, Treloar G, Iyer-Raniga U (2000) Life-cycle energy analysis of buildings: a case study. Build Res Inf 28: 31–41. https://doi.org/10.1080/096132100369073 doi: 10.1080/096132100369073
|
| [32] |
Menzies GF, Turan S, Banfill PF (2007) Life-cycle assessment and embodied energy: A review. Proc Inst Civ Eng Constr Mater 160: 135–143. https://doi.org/10.1680/coma.2007.160.4.135 doi: 10.1680/coma.2007.160.4.135
|
| [33] |
Ramesh T, Prakash R, Shukla KK (2010) Life cycle energy analysis of buildings: An overview. Energy Build 42: 1592–1600. https://doi.org/10.1016/j.enbuild.2010.05.007 doi: 10.1016/j.enbuild.2010.05.007
|
| [34] | NRMRL Staff. Life Cycle Assessment (LCA). EPA.gov. Washington, DC. EPA. National Risk Management Research Laboratory (NRMRL) March 6, 2012. Available from: https://web.archive.org/web/20120306122239/http://www.epa.gov/nrmrl/std/lca/lca.html. |
| [35] | Water Resources Agency. Available from: https://www.wrasb.gov.tw (In Chinese) (retrieved on September 18, 2022). |
| [36] | Bureau of Standards and Inspection, Ministry of Economic Affairs. Technical Specifications for high-efficiency solar modules in Taiwan (2016). |
| [37] | Motech Industries, Inc. Available from: (In Chinese): https://www.motech.com.tw/modules-1.php (retrieved on September 18, 2022). |
| [38] | Huffman DL, Antelme F (2009) Availability analysis of a solar power system with graceful degradation. In: Proceedings of the Reliability and Maintainability Symposium, Fort Worth, TX. https://doi.org/10.1109/RAMS.2009.4914701 |
| [39] |
Mann HB (1945) Nonparametric tests against trend. Econometrica 13: 245–259. https://doi.org/10.2307/1907187 doi: 10.2307/1907187
|
| [40] | Kendall MG (1975) Rank Correlation Methods, Griffin, London. Available from: https://www.scirp.org/(S(351jmbntvnsjt1aadkposzje))/reference/ReferencesPapers.aspx?ReferenceID = 2099295. |
| [41] | Salas JD (1993) Analysis and modeling of hydrologic time series. In Handbook of Hydrology, Maidment DR, McGraw-Hill: New York, 19.1-1302. Available from: https://www.scirp.org/(S(i43dyn45teexjx455qlt3d2q))/reference/ReferencesPapers.aspx?ReferenceID = 1186482. |
| [42] | Box GEP, Jenkins G M, Reinsel GC (1994) Time Series Analysis; Forecasting and Control, Third Edition, Prentice-Hall, Englewood Cliff, New Jersey. Available from: https://www.scirp.org/(S(i43dyn45teexjx455qlt3d2q))/reference/ReferencesPapers.aspx?ReferenceID = 1936224. |
| [43] | Bureau of Energy, Ministry of Economic Affairs. Available from (In Chinese): https://www.moeaidb.gov.tw/iphw/changpin/#open-modal. (retrieved on October 10, 2022). |
| [44] |
Staebler DL, Wronski CR (1977) Reversible conductivity changes in discharge‐produced amorphous Si. Appl Phys Lett 31: 292–294. https://doi.org/10.1063/1.89674 doi: 10.1063/1.89674
|
| [45] |
Ortiz O, Castells F, Sonnemann G (2009) Sustainability in the construction industry: a review of recent developments based on LCA. Constr Build Mater 23: 28–39. https://doi.org/10.1016/j.conbuildmat.2007.11.012 doi: 10.1016/j.conbuildmat.2007.11.012
|
| [46] | Motech Industries, Inc. Available from (In Chinese): https://www.motech.com.tw/green.php. |
| 1. | Dody Dwi Handoko, Anisa Maharani Kaseh, Laras Cempaka, Wahyudi David, Bram Kusbiantoro, Afifah Zahra Agista, Yusuke Ohsaki, Hitoshi Shirakawa, , Effects of household-scale cooking on volatile compounds, sensory profile, and hypotensive effect of Kenikir (Cosmos caudatus), 2023, 8, 2471-2086, 198, 10.3934/agrfood.2023011 | |
| 2. | A Short Review: Bioactivity of Fermented Rice Bran, 2021, 70, 1345-8957, 1565, 10.5650/jos.ess21190 | |
| 3. | Slamet BUDIJANTO, Lilis NURAIDA, Bambang Pontjo PRIOSOERYANTO, Uus SAEPULOH, Sela Septima MARYA, Hitoshi SHIRAKAWA, Fermented black rice bran extract inhibit colon cancer proliferation in WiDr cell lines, 2022, 42, 1678-457X, 10.1590/fst.14422 | |
| 4. | Yanping Chi, Lining Kang, Xiangying Liu, Hongrui Sun, Yue Meng, Jialin Zhang, You Kang, Yonggang Dai, Preparation, Purification, Characterization and Antioxidant Activity of Rice Bran Fermentation Broth with Hypsizigus marmoreus, 2024, 10, 2311-5637, 188, 10.3390/fermentation10040188 | |
| 5. | Kenneth Prudence Abasubong, Ndakalimwe Naftal Gabriel, Jean-Jacques Yao Adjoumani, 2024, Chapter 11, 978-981-97-4278-3, 243, 10.1007/978-981-97-4279-0_11 |
Figures(9) / Tables(3)
Ching-Feng CHEN. Offshore floating photovoltaic system energy returns assessment—A life cycle energy analysis-based perspective[J]. AIMS Energy, 2023, 11(3): 540-554. doi: 10.3934/energy.2023028
| Group | 0 h | 2 h | 4 h | 6 h |
| Control | 172.3 ± 13.1 | 172.0 ± 8.1 | 161.3 ± 6.5 | 168.0 ± 3.0 |
| CIF | 176.8 ± 9.1 | 175.3 ± 2.9 | 165.3 ± 13.3 | 166.8 ± 8.5 |
| Change b (%) | - | +1.9 | +2.4 | −0.7 |
| IPRF | 171.3 ± 5.0 | 152.3 ± 14.3 | 142.0 ± 12.4 | 141.5 ± 12.2* |
| Change b (%) | - | −12.9 | −13.6 | −18.7 |
| Note: a Values are given as means ± SD, n = 4. *A significantly different (p < 0.05) versus Control after statistical analysis by one-way analysis of variance using SPSS version 22 software (SPSS, Inc., Chicago, IL, USA) followed by Duncan's multiple range test. | ||||
DownLoad:
CSV
| Compounds | Codes | HMDB ID | Relative Concentrations (ppm) | Effects | References | |||
| Inpari 30 | Cempo Ireng | |||||||
| Non-fermented | Fermented | Non-fermented | Fermented | |||||
| (Amino acids) | ||||||||
| Meta-tyrosine | AA1 | 0059720 | ND | 0.0266* | ND | ND | Immunoprotective | [41] |
| Reduces metastasis | [42] | |||||||
| Norvaline | AA2 | 0013716 | 0.0253* | 0.0008* | ND | ND | Arginase inhibitor | [31] |
| N-Acetyltryptophan | AA3 | 0013713 | ND | 0.0039* | ND | ND | Antioxidant | [43] |
| 1H-Imidazole-1-acetic acid | AA4 | 0029736 | ND | ND | ND | 0.0033* | - | - |
| L-DOPA | AA5 | 0000181 | ND | ND | ND | 0.0050* | Treatment of Parkinson Dissease (by increasing dopamine levels in brain) | [44] |
| 3-Methyldioxyindole | AA6 | 0004186 | ND | ND | 0.0011 ± 0.0003 | ND | - | - |
| L-Phenylalanine | AA7 | 0000159 | ND | 0.2413 ± 0.2051a | ND | 0.0360 ± 0.0080b | Neurotransmitter synthesis, hormones and pigments synthesis | [26] |
| Indoleacrylic acid | AA8 | 0000734 | 0.0115*a | 0.1806 ± 0.1412b | ND | 0.0395 ± 0.0011a | Improves the instentines functions | [45] |
| (Carbohydrates) | ||||||||
| Succinic acid | KH | 0000254 | 0.0002* | ND | ND | ND | Antioxidant, Imrpove the immune and nervous functions | [46] |
| (Lipids) | ||||||||
| Cincassiol B | LD1 | 0036855 | ND | 0, 0208* | ND | ND | - | - |
| Lacinilene C 7-methyl ether | LD2 | 0036456 | 0.0129 ± 0.0015 | 0.0058* | 0.0134* | 0.0023* | Antimicrobial | [22] |
| Valdiic acid | LD3 | 0040980 | ND | 0.0088 ± 0.0108 | ND | ND | - | - |
| Prostaglandin C1(1-) | LD4 | 0062756 | 0.0102 ± 0.0029 | ND | 0.0090 ± 0.0017 | ND | - | - |
| 10-Oxo-11-octadecen-13-olide | LD5 | 0029786 | 0.0041* | ND | 0.0109* | ND | - | - |
| Aminocaproic acid | LD6 | 0001901 | ND | 0.0390* | ND | 0.0037* | Antifibrinolytic | [47] |
| L-Octanoylcarnitine | LD7 | 0000791 | ND | 0.0180* | 0.0091 ± 0.0052 | ND | - | - |
| Leukotriene A4 | LD8 | 0029016 | 0.0352 ± 0.0288 | 0.0131 ± 0.0063 | 0.0110* | ND | The parent molecule for the biosynthesis of all leukotrienes | [48] |
| Phytosphingosine | LD9 | 0004610 | ND | 0.0126*b | 0.0114 ± 0.0031a | 0.0049 ± 0.0042b | ● Anti-inlammatory and antibacterial in skin disorders | [31] |
| ● Activates the transcription activity on PPAR | [23] | |||||||
| (Ent-2alpha, 3beta, 15beta, 16beta)-15, 16-Epoxy-2, 3-kauranediol | LD10 | 0038688 | 0.0201 ± 0.0099b | ND | 0.0019*a | ND | - | - |
| Dehydroabietic acid | LD11 | 0031127 | 0.0263* | ND | ND | ND | ● Anti-inflammatory in obese people | [49] |
| ● Activates the SIRT1 enzymes | [50] | |||||||
| 13, 14-Dihydro-15-keto-PGE2 | LD12 | 0002776 | ND | ND | 0.0010* | ND | Increases the growth of pancreatic celss | [51] |
| 3-hydroxyundecanoyl carnitine | LD13 | 0061637 | ND | ND | 0.0102 ± 0.0031 | ND | - | - |
| Leukotriene C4 | LD14 | 0001198 | 0.0095* | ND | ND | ND | Lipid mediator for inflammation | [52] |
| 5-Hexyltetrahydro-2-furanoctanoic acid | LD15 | 0029018 | 0.0105* | ND | 0.0021* | ND | - | - |
| (Z)-13-Oxo-9-octadecenoic acid | LD16 | 0029796 | 0.0094* | 0.0072* | ND | ND | - | - |
| (Nucleotides) | ||||||||
| Adenosine | NA | 0000050 | 0.0838 ± 0.1053 | 0.4323 ± 0.1236 | 0.2119 ± 0.0142 | 0.3007 ± 0.1602 | ● Neuromodulator | [34] |
| ● Neuroprotective | [33] | |||||||
| ● Reduces epilepsy | [32] | |||||||
| ● Regulates the sleep cycle | [53] | |||||||
| ● Lowering blood pressure | [5] | |||||||
| (Secondary Metabolites) | ||||||||
| Cohumulone | MS1 | 0033981 | ND | 0.0052* | ND | ND | Aldo keto reductase inhibitors | [54] |
| 3-O-Methylmethyldopa | MS2 | 0142154 | ND | 0.0022 ± 0.0005 | ND | ND | - | - |
| 2, 6-Dimethoxy-4-propylphenol | MS3 | 0036226 | ND | 0.0007 ± 0.0001 | ND | ND | - | - |
| Alpha-curcumene | MS4 | 0059878 | ND | 0.0017±0.0004 | ND | ND | ● Antimicrobial | [55] |
| ● Induced apoptosis | [56] | |||||||
| Cuscohygrine | MS5 | 0030290 | ND | 0.0033* | 0.0051* | 0.0028* | - | - |
| 3-Tert-butyl-4-hydroxyanisole | MS6 | 0059925 | ND | 0.0015* | 0.0184* | ND | The building blocks of butylated hydroxyanisole (BHA) | [57] |
| Momilactone B | MS7 | 0036749 | ND | 0.0153* | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| ● Cancer chemopreventive | [19] | |||||||
| 2-Indolecarboxylic acid | MS8 | 0002285 | 0.0024* | ND | 0.0023* | ND | Antioxidant | [58] |
| Kojic acid | MS9 | 0032923 | 0.0061 ± 0.0016 | ND | 0.0103 ± 0.0010 | ND | ● Tyrosinase inhibitors | [59] |
| ● Immunomodulator | [9] | |||||||
| L-1, 2, 3, 4-Tetrahydro-beta-carboline-3-carboxylic acid | MS10 | 0035665 | 0.0008* | ND | ND | ND | - | - |
| 4-Methylbenzoic acid | MS11 | 0029635 | 0.0010*a | ND | ND | 0.0385 ± 0.0103b | - | - |
| 2-Methylhippuric acid | MS12 | 0011723 | 0.0006* | ND | ND | ND | - | - |
| Momilactone A | MS13 | 0036748 | 0.0020* | ND | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| Coumarin | MS14 | 0001218 | 0.0009* | ND | ND | ND | ● Antimicrobial | [60) |
| ● Acetylcholinesterase (AChE) inhibitor | [61] | |||||||
| Quercetin | MS15 | 0005794 | ND | ND | 0.0050 ± 0.0031 | 0.0057 ± 0.0028 | ● Antioxidant | [62] |
| ● Decreases activation of dendytic celss for the treatment of inflammation, autoimmunity and transplantation | [61] | |||||||
| ● Antiviral activity against dengue fever | [63] | |||||||
| ● Lowering blood pressure in people with hypertension | [64] | |||||||
| ● Reduces symptoms of non-alcoholic fatty liver dissease | [65] | |||||||
| Isorhamnetin 7-glucoside | MS16 | 0029479 | ND | ND | 0.0089 ± 0.0050 | 0.0165 ± 0.0009 | Antioxidant | [66] |
| Isorhamnetin | MS17 | 0002655 | ND | ND | 0.0048* | 0.0121* | Treats cerebral vascular complications associated with diabetes | [67] |
| 2-Hydroxy-2-phenylpropanoic acid | MS18 | 0142137 | ND | ND | 0.0045 ± 0.0007a | 0.0029 ± 0.0013b | - | - |
| 2-Phenylpropionaldehyde dimethyl acetal | MS19 | 0032468 | ND | ND | ND | 0.0055 ± 0.0022 | - | - |
| Naringenin | MS20 | 0002670 | ND | ND | ND | 0.0037* | ● Hepatoprotector | [68] |
| ● Reduces TNF- α production | [69] | |||||||
| ● Anti-hyperglycemia | [70] | |||||||
| ● Cardioprotective | [71] | |||||||
| ● Antiviral activity against dengue fever | [72] | |||||||
| ● Inhibits the proliferation and migration of prostate cancer cells | [73] | |||||||
| Phenprocoumon | MS21 | 0015081 | ND | ND | ND | 0.0058* | ● Anticoagulant | [74] |
| Isovanillic acid | MS22 | 0060003 | ND | ND | 0.0042 ± 0.0011 | ND | ● Antibacterial | [75] |
| ● Antioxidant | [76] | |||||||
| Antimicrobial | [60] | |||||||
| 2, 6-Dimethoxybenzoic acid | MS23 | 0029273 | ND | ND | 0.0106* | ND | - | - |
| Benzoic acid | MS24 | 0001870 | ND | ND | 0.0009 ± 0.0003 | ND | Inhibits the growth of resistant bacteria | [77] |
| N, N-diethyl phenylacetamide | MS25 | 0032635 | 0.0090* | 0.0096* | 0.0066* | 0.0263* | Mosquitos repellent | [17] |
| Oryzalide B | MS27 | 0037592 | ND | ND | ND | 0.0053 ± 0.0032 | Antibacterial | [78] |
| Acetylvalerenolic acid | MS28 | 0035687 | ND | ND | ND | 0.0045* | - | - |
| MS29 | 0035882 | ND | 0.0309 | ND | ND | Hepatoprotector | [18] | |
| Dimboa-glc | MS30 | 0029710 | ND | ND | 0.0089 ± 0.0056 | ND | - | - |
| 2-Decylfuran | MS31 | 0032215 | ND | ND | ND | 0.0015 | - | - |
| Piperenol A triacetate | MS32 | 0041535 | ND | 0.0129* | ND | ND | - | - |
| Ginsenoyne G | MS33 | 0039589 | ND | ND | 0.0025 | ND | - | - |
| Acetylpterosin C | MS34 | 0030764 | 0.0053* | ND | ND | ND | - | - |
| 1, 3, 11-Tridecatriene-5, 7, 9-triyne | MS35 | 0034294 | ND | ND | 0.0160 | ND | - | - |
| Myrigalone A | MS36 | 0037245 | ND | ND | 0.0278* | 0.0256* | Antibacterial | [79] |
| (Vitamins dan cofactors) | ||||||||
| Nicotinic acid | VK1 | 0001488 | 0.0114 ± 0.0007 | ND | 0.0060 ± 0.0025 | 0.0076 ± 0.0009 | Increases HDL cholesterol and lowers triglycerides for the treatment of atherosclerosis | [29] |
| Pantothenic acid | VK2 | 0000210 | ND | ND | ND | 0.0028 ± 0.0010 | Substrates for the synthesis of coenzyme A and ACP (acyl carrier protein) | [80] |
| 2-Hydroxypyridine | VK3 | 0013751 | 0.0008* | ND | ND | ND | - | - |
| 4-Methyl-5-thiazoleethanol | VK4 | - | 0.0175 ± 0.0014 | ND | 0.0066 ± 0.0021 | ND | - | - |
| Trigonelline | VK5 | 0000875 | 0.0344 ± 0.0247 | ND | ND | ND | ● Increases cell sensitivity to anticancer and apoptotic drugs | [81] |
| ● Prevents gastric ulcer induced by indomethacin | [82] | |||||||
| ● Lowering blood sugar and lipid as well as increasing insulin sensitivity for diabetes | ||||||||
| ● Inhibits neurons loss in hypocampus | [83] | |||||||
| 7-Aminomethyl-7-carbaguanine | VK6 | 0011690 | ND | ND | ND | 0.0132* | - | - |
| Pyridoxal | VK7 | 0001545 | ND | ND | 0.0066 ± 0.0021 | ND | ● Cofactors in various amino acids metabolism | [84] |
| ● Maintains the nervous systems in infants | [85] | |||||||
| (Peptides) | ||||||||
| Leucyl-valine | PD1 | 0028942 | ND | 0.0222 ± 0.0162 | ND | ND | Increases the expression of glutathione peroxidase, antioxidants and cell protection agents | [86] |
| Leucyl-isoleucine | PD2 | 0028932 | ND | 0.0653 ± 0.0436 | ND | 0.0596 ± 0.0263 | Increases the stimulation of AMPK phosphorylation (5'-AMP protein kinase), monocytes, and platelets | [30] |
| Note: The presentation of the relative value data for the compounds comes from the calculation of the average relative area of the compound from 3 replications ± deviation standard; ND = Not Detected; * = compound obtained only in 1 replication; Numbers on the same line with different letters indicate significant differences (p < 0.05). | ||||||||
DownLoad:
CSV
| Group | 0 h | 2 h | 4 h | 6 h |
| Control | 172.3 ± 13.1 | 172.0 ± 8.1 | 161.3 ± 6.5 | 168.0 ± 3.0 |
| CIF | 176.8 ± 9.1 | 175.3 ± 2.9 | 165.3 ± 13.3 | 166.8 ± 8.5 |
| Change b (%) | - | +1.9 | +2.4 | −0.7 |
| IPRF | 171.3 ± 5.0 | 152.3 ± 14.3 | 142.0 ± 12.4 | 141.5 ± 12.2* |
| Change b (%) | - | −12.9 | −13.6 | −18.7 |
| Note: a Values are given as means ± SD, n = 4. *A significantly different (p < 0.05) versus Control after statistical analysis by one-way analysis of variance using SPSS version 22 software (SPSS, Inc., Chicago, IL, USA) followed by Duncan's multiple range test. | ||||
| Compounds | Codes | HMDB ID | Relative Concentrations (ppm) | Effects | References | |||
| Inpari 30 | Cempo Ireng | |||||||
| Non-fermented | Fermented | Non-fermented | Fermented | |||||
| (Amino acids) | ||||||||
| Meta-tyrosine | AA1 | 0059720 | ND | 0.0266* | ND | ND | Immunoprotective | [41] |
| Reduces metastasis | [42] | |||||||
| Norvaline | AA2 | 0013716 | 0.0253* | 0.0008* | ND | ND | Arginase inhibitor | [31] |
| N-Acetyltryptophan | AA3 | 0013713 | ND | 0.0039* | ND | ND | Antioxidant | [43] |
| 1H-Imidazole-1-acetic acid | AA4 | 0029736 | ND | ND | ND | 0.0033* | - | - |
| L-DOPA | AA5 | 0000181 | ND | ND | ND | 0.0050* | Treatment of Parkinson Dissease (by increasing dopamine levels in brain) | [44] |
| 3-Methyldioxyindole | AA6 | 0004186 | ND | ND | 0.0011 ± 0.0003 | ND | - | - |
| L-Phenylalanine | AA7 | 0000159 | ND | 0.2413 ± 0.2051a | ND | 0.0360 ± 0.0080b | Neurotransmitter synthesis, hormones and pigments synthesis | [26] |
| Indoleacrylic acid | AA8 | 0000734 | 0.0115*a | 0.1806 ± 0.1412b | ND | 0.0395 ± 0.0011a | Improves the instentines functions | [45] |
| (Carbohydrates) | ||||||||
| Succinic acid | KH | 0000254 | 0.0002* | ND | ND | ND | Antioxidant, Imrpove the immune and nervous functions | [46] |
| (Lipids) | ||||||||
| Cincassiol B | LD1 | 0036855 | ND | 0, 0208* | ND | ND | - | - |
| Lacinilene C 7-methyl ether | LD2 | 0036456 | 0.0129 ± 0.0015 | 0.0058* | 0.0134* | 0.0023* | Antimicrobial | [22] |
| Valdiic acid | LD3 | 0040980 | ND | 0.0088 ± 0.0108 | ND | ND | - | - |
| Prostaglandin C1(1-) | LD4 | 0062756 | 0.0102 ± 0.0029 | ND | 0.0090 ± 0.0017 | ND | - | - |
| 10-Oxo-11-octadecen-13-olide | LD5 | 0029786 | 0.0041* | ND | 0.0109* | ND | - | - |
| Aminocaproic acid | LD6 | 0001901 | ND | 0.0390* | ND | 0.0037* | Antifibrinolytic | [47] |
| L-Octanoylcarnitine | LD7 | 0000791 | ND | 0.0180* | 0.0091 ± 0.0052 | ND | - | - |
| Leukotriene A4 | LD8 | 0029016 | 0.0352 ± 0.0288 | 0.0131 ± 0.0063 | 0.0110* | ND | The parent molecule for the biosynthesis of all leukotrienes | [48] |
| Phytosphingosine | LD9 | 0004610 | ND | 0.0126*b | 0.0114 ± 0.0031a | 0.0049 ± 0.0042b | ● Anti-inlammatory and antibacterial in skin disorders | [31] |
| ● Activates the transcription activity on PPAR | [23] | |||||||
| (Ent-2alpha, 3beta, 15beta, 16beta)-15, 16-Epoxy-2, 3-kauranediol | LD10 | 0038688 | 0.0201 ± 0.0099b | ND | 0.0019*a | ND | - | - |
| Dehydroabietic acid | LD11 | 0031127 | 0.0263* | ND | ND | ND | ● Anti-inflammatory in obese people | [49] |
| ● Activates the SIRT1 enzymes | [50] | |||||||
| 13, 14-Dihydro-15-keto-PGE2 | LD12 | 0002776 | ND | ND | 0.0010* | ND | Increases the growth of pancreatic celss | [51] |
| 3-hydroxyundecanoyl carnitine | LD13 | 0061637 | ND | ND | 0.0102 ± 0.0031 | ND | - | - |
| Leukotriene C4 | LD14 | 0001198 | 0.0095* | ND | ND | ND | Lipid mediator for inflammation | [52] |
| 5-Hexyltetrahydro-2-furanoctanoic acid | LD15 | 0029018 | 0.0105* | ND | 0.0021* | ND | - | - |
| (Z)-13-Oxo-9-octadecenoic acid | LD16 | 0029796 | 0.0094* | 0.0072* | ND | ND | - | - |
| (Nucleotides) | ||||||||
| Adenosine | NA | 0000050 | 0.0838 ± 0.1053 | 0.4323 ± 0.1236 | 0.2119 ± 0.0142 | 0.3007 ± 0.1602 | ● Neuromodulator | [34] |
| ● Neuroprotective | [33] | |||||||
| ● Reduces epilepsy | [32] | |||||||
| ● Regulates the sleep cycle | [53] | |||||||
| ● Lowering blood pressure | [5] | |||||||
| (Secondary Metabolites) | ||||||||
| Cohumulone | MS1 | 0033981 | ND | 0.0052* | ND | ND | Aldo keto reductase inhibitors | [54] |
| 3-O-Methylmethyldopa | MS2 | 0142154 | ND | 0.0022 ± 0.0005 | ND | ND | - | - |
| 2, 6-Dimethoxy-4-propylphenol | MS3 | 0036226 | ND | 0.0007 ± 0.0001 | ND | ND | - | - |
| Alpha-curcumene | MS4 | 0059878 | ND | 0.0017±0.0004 | ND | ND | ● Antimicrobial | [55] |
| ● Induced apoptosis | [56] | |||||||
| Cuscohygrine | MS5 | 0030290 | ND | 0.0033* | 0.0051* | 0.0028* | - | - |
| 3-Tert-butyl-4-hydroxyanisole | MS6 | 0059925 | ND | 0.0015* | 0.0184* | ND | The building blocks of butylated hydroxyanisole (BHA) | [57] |
| Momilactone B | MS7 | 0036749 | ND | 0.0153* | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| ● Cancer chemopreventive | [19] | |||||||
| 2-Indolecarboxylic acid | MS8 | 0002285 | 0.0024* | ND | 0.0023* | ND | Antioxidant | [58] |
| Kojic acid | MS9 | 0032923 | 0.0061 ± 0.0016 | ND | 0.0103 ± 0.0010 | ND | ● Tyrosinase inhibitors | [59] |
| ● Immunomodulator | [9] | |||||||
| L-1, 2, 3, 4-Tetrahydro-beta-carboline-3-carboxylic acid | MS10 | 0035665 | 0.0008* | ND | ND | ND | - | - |
| 4-Methylbenzoic acid | MS11 | 0029635 | 0.0010*a | ND | ND | 0.0385 ± 0.0103b | - | - |
| 2-Methylhippuric acid | MS12 | 0011723 | 0.0006* | ND | ND | ND | - | - |
| Momilactone A | MS13 | 0036748 | 0.0020* | ND | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| Coumarin | MS14 | 0001218 | 0.0009* | ND | ND | ND | ● Antimicrobial | [60) |
| ● Acetylcholinesterase (AChE) inhibitor | [61] | |||||||
| Quercetin | MS15 | 0005794 | ND | ND | 0.0050 ± 0.0031 | 0.0057 ± 0.0028 | ● Antioxidant | [62] |
| ● Decreases activation of dendytic celss for the treatment of inflammation, autoimmunity and transplantation | [61] | |||||||
| ● Antiviral activity against dengue fever | [63] | |||||||
| ● Lowering blood pressure in people with hypertension | [64] | |||||||
| ● Reduces symptoms of non-alcoholic fatty liver dissease | [65] | |||||||
| Isorhamnetin 7-glucoside | MS16 | 0029479 | ND | ND | 0.0089 ± 0.0050 | 0.0165 ± 0.0009 | Antioxidant | [66] |
| Isorhamnetin | MS17 | 0002655 | ND | ND | 0.0048* | 0.0121* | Treats cerebral vascular complications associated with diabetes | [67] |
| 2-Hydroxy-2-phenylpropanoic acid | MS18 | 0142137 | ND | ND | 0.0045 ± 0.0007a | 0.0029 ± 0.0013b | - | - |
| 2-Phenylpropionaldehyde dimethyl acetal | MS19 | 0032468 | ND | ND | ND | 0.0055 ± 0.0022 | - | - |
| Naringenin | MS20 | 0002670 | ND | ND | ND | 0.0037* | ● Hepatoprotector | [68] |
| ● Reduces TNF- α production | [69] | |||||||
| ● Anti-hyperglycemia | [70] | |||||||
| ● Cardioprotective | [71] | |||||||
| ● Antiviral activity against dengue fever | [72] | |||||||
| ● Inhibits the proliferation and migration of prostate cancer cells | [73] | |||||||
| Phenprocoumon | MS21 | 0015081 | ND | ND | ND | 0.0058* | ● Anticoagulant | [74] |
| Isovanillic acid | MS22 | 0060003 | ND | ND | 0.0042 ± 0.0011 | ND | ● Antibacterial | [75] |
| ● Antioxidant | [76] | |||||||
| Antimicrobial | [60] | |||||||
| 2, 6-Dimethoxybenzoic acid | MS23 | 0029273 | ND | ND | 0.0106* | ND | - | - |
| Benzoic acid | MS24 | 0001870 | ND | ND | 0.0009 ± 0.0003 | ND | Inhibits the growth of resistant bacteria | [77] |
| N, N-diethyl phenylacetamide | MS25 | 0032635 | 0.0090* | 0.0096* | 0.0066* | 0.0263* | Mosquitos repellent | [17] |
| Oryzalide B | MS27 | 0037592 | ND | ND | ND | 0.0053 ± 0.0032 | Antibacterial | [78] |
| Acetylvalerenolic acid | MS28 | 0035687 | ND | ND | ND | 0.0045* | - | - |
| MS29 | 0035882 | ND | 0.0309 | ND | ND | Hepatoprotector | [18] | |
| Dimboa-glc | MS30 | 0029710 | ND | ND | 0.0089 ± 0.0056 | ND | - | - |
| 2-Decylfuran | MS31 | 0032215 | ND | ND | ND | 0.0015 | - | - |
| Piperenol A triacetate | MS32 | 0041535 | ND | 0.0129* | ND | ND | - | - |
| Ginsenoyne G | MS33 | 0039589 | ND | ND | 0.0025 | ND | - | - |
| Acetylpterosin C | MS34 | 0030764 | 0.0053* | ND | ND | ND | - | - |
| 1, 3, 11-Tridecatriene-5, 7, 9-triyne | MS35 | 0034294 | ND | ND | 0.0160 | ND | - | - |
| Myrigalone A | MS36 | 0037245 | ND | ND | 0.0278* | 0.0256* | Antibacterial | [79] |
| (Vitamins dan cofactors) | ||||||||
| Nicotinic acid | VK1 | 0001488 | 0.0114 ± 0.0007 | ND | 0.0060 ± 0.0025 | 0.0076 ± 0.0009 | Increases HDL cholesterol and lowers triglycerides for the treatment of atherosclerosis | [29] |
| Pantothenic acid | VK2 | 0000210 | ND | ND | ND | 0.0028 ± 0.0010 | Substrates for the synthesis of coenzyme A and ACP (acyl carrier protein) | [80] |
| 2-Hydroxypyridine | VK3 | 0013751 | 0.0008* | ND | ND | ND | - | - |
| 4-Methyl-5-thiazoleethanol | VK4 | - | 0.0175 ± 0.0014 | ND | 0.0066 ± 0.0021 | ND | - | - |
| Trigonelline | VK5 | 0000875 | 0.0344 ± 0.0247 | ND | ND | ND | ● Increases cell sensitivity to anticancer and apoptotic drugs | [81] |
| ● Prevents gastric ulcer induced by indomethacin | [82] | |||||||
| ● Lowering blood sugar and lipid as well as increasing insulin sensitivity for diabetes | ||||||||
| ● Inhibits neurons loss in hypocampus | [83] | |||||||
| 7-Aminomethyl-7-carbaguanine | VK6 | 0011690 | ND | ND | ND | 0.0132* | - | - |
| Pyridoxal | VK7 | 0001545 | ND | ND | 0.0066 ± 0.0021 | ND | ● Cofactors in various amino acids metabolism | [84] |
| ● Maintains the nervous systems in infants | [85] | |||||||
| (Peptides) | ||||||||
| Leucyl-valine | PD1 | 0028942 | ND | 0.0222 ± 0.0162 | ND | ND | Increases the expression of glutathione peroxidase, antioxidants and cell protection agents | [86] |
| Leucyl-isoleucine | PD2 | 0028932 | ND | 0.0653 ± 0.0436 | ND | 0.0596 ± 0.0263 | Increases the stimulation of AMPK phosphorylation (5'-AMP protein kinase), monocytes, and platelets | [30] |
| Note: The presentation of the relative value data for the compounds comes from the calculation of the average relative area of the compound from 3 replications ± deviation standard; ND = Not Detected; * = compound obtained only in 1 replication; Numbers on the same line with different letters indicate significant differences (p < 0.05). | ||||||||
